- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Amgen's First-in-Class Viral Drug, T-Vec, Could Soon Be Approved by EMA
The drug is awaiting an FDA verdict next week.
The European Medicine Agency (EMA) has approved Amgen's tumor-killing virus, talimogene laherparepvec (T-Vec) for treating unresectable melanoma that has not metastasized. Imlygic uses a modified herpes simplex virus that is targeted to infect cancer cells alone. The virus, injected directly into the tumors, replicates and causes the cancer cells to rupture. The resulting immune system response is responsible for the antigenic response against the tumor.
The product is due for an FDA verdict by October 27, 2015.
Read more here: http://reut.rs/1W9QCJA.
Elevated Inflammatory Marker Levels Associated With Increased Overactive Bladder Risk
April 15th 2025Systemic immune inflammation index, neutrophil-to-lymphocyte ratio, and systemic inflammation response index levels may offer a noninvasive method to identify individuals at increased risk of developing overactive bladder.
Read More
